MET
58
2
ORCL
49
3
NKE
36
2
HAS
29
3
AA
27
5
STZ
42
2
CCI
30
2
CNP
59
17
JCI
44
7
MSFT
55
2
OMC
37
2
OI
23
3
MTCH
62
22
JBHT
46
4
GRMN
53
3
VFC
56
6
PNR
56
2
FSLR
50
6
BIIB
36
8
SPG
45
2
MET
58
2
ORCL
49
3
NKE
36
2
HAS
29
3
AA
27
5
STZ
42
2
CCI
30
2
CNP
59
17
JCI
44
7
MSFT
55
2
OMC
37
2
OI
23
3
MTCH
62
22
JBHT
46
4
GRMN
53
3
VFC
56
6
PNR
56
2
FSLR
50
6
BIIB
36
8
SPG
45
2
Financhill
Back

Grace Therapeutics 10K Form

Buy
52

GRCE
Grace Therapeutics

Last Price:
$3.88
Seasonality Move:
12.25%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive GRCE News And Ratings

See the #1 stock for the next 7 days that we like better than GRCE

GRCE Financial Statistics

Sales & Book Value

Annual Sales: $196K
Cash Flow: $-4.2M
Price / Cash Flow: 0
Annual Sales: $5.54
Price / Book: 0.69

Profitability

EPS (TTM): -1.29460
Net Income (TTM): $-11.6M
Gross Margin: $120K
Return on Equity: 0%
Return on Assets: 0%

Grace Therapeutics Earnings Forecast

Key Grace Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 12 years for GRCE is 61.22%.
  • The Selling, General & Administrative Expenses for GRCE have been equal to 3,395.41% of Gross Profit Margin.
  • The Interest Expense is -0.97% of Operating Income.
  • Per Share Earnings over the last 15 years have been positive in 8 years.

Grace Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: GRCE
Website: acastipharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

GRCE Technical Analysis vs Fundamental Analysis

Buy
52
Grace Therapeutics (GRCE) is a Buy

Is Grace Therapeutics a Buy or a Sell?